페닐케톤뇨증(PKU) 치료제 시장, 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Phenylketonuria (PKU) Treatment Market was valued at USD 737.7 million in 2023 and is projected to expand at a CAGR of 7.2% from 2024 to 2032. The rising demand for PKU treatments is driven by a global increase in PKU cases and advancements in treatment methods.

Enhanced newborn screening initiatives facilitate earlier PKU detections, boosting the demand for effective management therapies. Concurrently, active research and development are producing innovative therapeutic options, including gene therapy and novel drug formulations, which promise improved patient outcomes. For instance, in November 2023, the Perelman School of Medicine at the University of Pennsylvania unveiled research on future treatments using advanced CRISPR gene editing techniques, specifically prime and base editing. These advancements are poised to introduce groundbreaking therapies in genetic medicine. Moreover, increased awareness among healthcare professionals and patients about the benefits of timely and sustained treatment is further driving the PKU treatment market.

The overall phenylketonuria treatment market is classified based on PKU type, treatment type, age group, route of administration, end-user, and region.

Classic PKU segment is estimated to grow at a 7% CAGR through 2032. Its prevalence and the necessity for lifelong management underscore its market dominance. Stringent dietary controls and constant monitoring are essential for classic PKU patients. This form of PKU drives the demand for treatments like dietary supplements, medications, and emerging therapies. The extensive management needs and sizable patient population lead to a market focus on solutions that effectively regulate phenylalanine levels and prevent long-term complications.

In 2023, drug therapy emerged as the leading segment, capturing a market share of 54.5%. This prominence is due to drug therapy's crucial role in managing PKU, especially for patients who struggle to maintain control through dietary measures alone. Medications, including sapropterin dihydrochloride and other emerging therapies, play a vital role in lowering blood phenylalanine levels, leading to significant improvements in patient outcomes. The expanding availability of targeted drug therapies and advancements in pharmacological treatments are addressing unmet needs and increasing market demand. Furthermore, these drug therapies complement dietary management, fostering more comprehensive and adaptable treatment regimens for PKU patients.

In 2023, the U.S. phenylketonuria treatment market was valued at USD 280.6 million, with projections pointing towards USD 502.5 million by 2032. This robust growth is largely due to breakthroughs in diagnostic and therapeutic technologies. Innovations in genetic testing and specialized medical foods are revolutionizing PKU management, emphasizing early detection and personalized treatment strategies. The integration of advanced technologies, like next-generation sequencing, is refining genetic testing accuracy and enhancing dietary management products. These technological strides not only bolster treatment outcomes but also create lucrative opportunities for the market players in the U.S.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of PKU
    • 3.2.1.2 Advancements in new therapies for PKU
    • 3.2.1.3 Enhanced newborn screening programs
    • 3.2.1.4 Growing awareness for early screening and treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Pipeline analysis
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By PKU Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Classic PKU
• 5.3 Mild PKU
• 5.4 Moderate or variant PKU
• 5.5 Hyperphenylalaninemia

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug therapy
• 6.3 Dietary management
• 6.4 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatrics
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Specialty clinics
• 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 American Gene Technologies
• 11.3 APR Applied Pharma Research s.a.
• 11.4 BioMarin Pharmaceutical Inc.
• 11.5 Codexis, Inc.
• 11.6 Erytech Pharma SA
• 11.7 Homology Medicines, Inc.
• 11.8 Lysogene S.A.
• 11.9 PIAM Farmaceutici S.P.A.
• 11.10 Pluvia AS
• 11.11 PTC Therapeutics
• 11.12 SOM Innovation Biotech SL
• 11.13 Synlogic
• 11.14 Ultragenyx (Dimension Therapeutics)
• 11.15 Vitaflo International Ltd.